Acumen Pharmaceuticals (ABOS) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T12:50:18.157Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:50:18.157Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.13
Unrounded diluted TTM EPS · period ending 2026-06-30: -1.64

FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ABOS PE Ratio Metrics

PE RATIO

N/A

ABOS Competitors' PE Ratio

ABOS

Acumen Pharmaceuticals, Inc.

Current

Market Cap

$153.84M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVXL

Anavex Life Sciences Corp.

vs ABOS

Market Cap

$152.45M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRDL

Cardiol Therapeutics Inc.

vs ABOS

Market Cap

$152.16M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDXS

Codexis, Inc.

vs ABOS

Market Cap

$149.51M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INGN

Inogen, Inc.

vs ABOS

Market Cap

$160.82M

PE Ratio

N/A

TTM Avg

65.68

3Y Avg

52.50

5Y Avg

80.75

IMRX

Immuneering Corporation

vs ABOS

Market Cap

$146.66M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALXO

ALX Oncology Holdings Inc.

vs ABOS

Market Cap

$162.82M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FBIOP

Fortress Biotech, Inc.

vs ABOS

Market Cap

$142.49M

PE Ratio

6.75

TTM Avg

6.25

3Y Avg

6.25

5Y Avg

6.25

ACOG

Alpha Cognition Inc

vs ABOS

Market Cap

$142.11M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FRNM

Freenome, Inc.

vs ABOS

Market Cap

$137.29M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Acumen Pharmaceuticals, Inc. (ABOS)	$153.84M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$152.45M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$152.16M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$149.51M	N/A	N/A	N/A	N/A
Inogen, Inc. (INGN)vs ›	$160.82M	N/A	65.68	52.50	80.75
Immuneering Corporation (IMRX)vs ›	$146.66M	N/A	N/A	N/A	N/A
ALX Oncology Holdings Inc. (ALXO)vs ›	$162.82M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIOP)vs ›	$142.49M	6.75	6.25	6.25	6.25
Alpha Cognition Inc (ACOG)vs ›	$142.11M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$137.29M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.13

÷

Forward EPS (Est.)

$-1.53

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ABOS PE Ratio Metrics

ABOS Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics